NRAS G13R clinical trials at UCSF

1 research study open to eligible people

NRAS G13R is a change in the NRAS gene at position 13 that can drive cancer. UCSF is testing a new drug in an early human study to check safety, dosing, and how the body handles the drug. UCSF is also studying drug effects in NRAS G13R solid tumors.

Showing trials for

  • First-in-human Study of RLY-8161 in Advanced NRAS-Mutant Solid Tumors

    open to eligible people ages 18 years and up

    This is a Phase 1 first-in-human, open-label multicenter study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of RLY-8161, an NRAS-selective inhibitor, in participants with advanced NRAS-mutant melanoma and other solid tumors.

    San Francisco, California and other locations

Last updated: